 |
 Video: What is a Stock Split?
|
|
|
| Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. According to our Precigen stock split history records, Precigen has had 0 splits. | |
|
Precigen (PGEN) has 0 splits in our Precigen stock split history database.
Looking at the Precigen stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Precigen shares, starting with a $10,000 purchase of PGEN, presented on a split-history-adjusted basis factoring in the complete Precigen stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$21.10 |
|
| End price/share: |
$1.31 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-93.79% |
|
| Average Annual Total Return: |
-24.28% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$620.54 |
|
| Years: |
9.99 |
|
|
|
|
|
